Stanislaw Wasiliew

Mr. Stanislaw Wasiliew

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in Artery Research
Verified
Journal Article
Open access
PDF file
SWStanislaw Wasiliew
Stanislaw Wasiliew
DLDawid Lipski
Dawid Lipski
LSLukasz Stryczynski
Lukasz Stryczynski
ARArtur Radziemski
Artur Radziemski
JKJan Królak
Jan Królak
Paweł UruskiPaweł Uruski
Paweł Uruski
Background: Resistant hypertension affects 10–15% of treated patients and remains a therapeutic challenge. Eplerenone is recommended when spironolactone is ineffective or poorly tolerated. Central blood pressure (BP) correlates more strongly with cardiovascular complications than peripheral BP, and pulse wave velocity (PWV) reflects arterial stiffness, a key factor in hypertension-related morbidity. While spironolactone is well-established for resistant hypertension, data on eplerenone’s efficacy and safety for this indication is limited. Interleukin-6 (IL-6) is involved in resistant hypertension and the pressor response to angiotensin II, with elevated levels suggesting its role in aldosterone regulation and potential as a therapeutic target. This study aimed to evaluate the efficacy of eplerenone (25–50 mg/day) on central aortic BP, PWV, office BP, ambulatory BP monitoring (ABPM), and IL-6 levels after four weeks. Twenty-seven patients with confirmed resistant hypertension received eplerenone for four weeks. Office BP, ABPM, central aortic BP, PWV, and safety markers (potassium, creatinine) were measured. IL-6 levels were assessed at baseline and post-treatment. Results: Significant reductions were observed in office BP (SBP: −13.93 mmHg, DBP: −7.64 mmHg), aortic BP (SBP: −13.42 mmHg, DBP: −7.94 mmHg), 24 h-ABPM (SBP: −7 mmHg, DBP: −3 mmHg), and PWV (− 1.52 m/s). Doubling the eplerenone dose from 25 mg to 50 mg daily reduces aortic systolic blood pressure threefold. IL-6 levels also decreased significantly ( p = 0.023). Conclusions: Eplerenone effectively reduces central and peripheral BP, arterial stiffness, and IL-6 levels, potentially lowering cardiovascular risk in resistant hypertension.